Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional

Evaluation of AVE5026 in the Prevention of Venous Thromboembolism in Cancer Patients Undergoing Chemotherapy

ClinicalTrials.gov ID: NCT00694382

Public ClinicalTrials.gov record NCT00694382. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 8:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Multinational, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AVE5026 in the Prevention of Venous Thromboembolism (VTE) in Cancer Patients at High Risk for VTE and Who Are Undergoing Chemotherapy

Study identification

NCT ID
NCT00694382
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Sanofi
Industry
Enrollment
3,212 participants

Conditions and interventions

Interventions

  • Placebo (for semuloparin) Drug
  • Semuloparin sodium Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2008
Primary completion
Oct 31, 2010
Completion
Oct 31, 2010
Last update posted
Jan 22, 2013

2008 – 2010

United States locations

U.S. sites
48
U.S. states
20
U.S. cities
46
Facility City State ZIP Site status
Investigational Site Number 840006 Birmingham Alabama 35211
Investigational Site Number 840007 Casa Grande Arizona 85222
Investigational Site Number 840060 Tucson Arizona 85704
Investigational Site Number 840050 Fountain Valley California 92708
Investigational Site Number 840072 Fullerton California 92835
Investigational Site Number 840037 Indian Wells California 92210
Investigational Site Number 840069 La Verne California 91750
Investigational Site Number 840009 Long Beach California 90806
Investigational Site Number 840001 Oceanside California 92056
Investigational Site Number 840011 Rancho Mirage California 92270
Investigational Site Number 840029 West Covina California 91790
Investigational Site Number 840005 Norwich Connecticut 06360
Investigational Site Number 840064 Torrington Connecticut 06790
Investigational Site Number 840038 Woodbridge Connecticut 06525
Investigational Site Number 840052 Washington D.C. District of Columbia 20010
Investigational Site Number 840025 Washington D.C. District of Columbia 20017
Investigational Site Number 840074 Clearwater Florida 33756
Investigational Site Number 840019 Jacksonville Florida 32207
Investigational Site Number 840051 Rockledge Florida 32955
Investigational Site Number 840073 Sarasota Florida 34239
Investigational Site Number 840070 Roswell Georgia 30076
Investigational Site Number 840016 Park Ridge Illinois 60068
Investigational Site Number 840028 Quincy Illinois 62301
Investigational Site Number 840008 Skokie Illinois 60077
Investigational Site Number 840033 Goshen Indiana 46526
Investigational Site Number 840010 Indianapolis Indiana 46237
Investigational Site Number 840014 Louisville Kentucky 40202
Investigational Site Number 840048 Mount Sterling Kentucky 40353
Investigational Site Number 840047 Metairie Louisiana 70056
Investigational Site Number 840032 Ruston Louisiana 71270
Investigational Site Number 840042 Bethesda Maryland 20817
Investigational Site Number 840066 Easton Maryland 21601
Investigational Site Number 840059 Tupelo Mississippi 38801
Investigational Site Number 840024 Rochester New York 14642
Investigational Site Number 840031 Syracuse New York 13210
Investigational Site Number 840020 Durham North Carolina 27710
Investigational Site Number 840021 Durham North Carolina 27710
Investigational Site Number 840026 High Point North Carolina 27262
Investigational Site Number 840046 Bismarck North Dakota 58501
Investigational Site Number 840003 Middletown Ohio 45042
Investigational Site Number 840022 Sylvania Ohio 43560
Investigational Site Number 840075 East Providence Rhode Island 02915
Investigational Site Number 840067 Beaumont Texas 77701
Investigational Site Number 840004 El Paso Texas 79915
Investigational Site Number 840034 Houston Texas 77030
Investigational Site Number 840035 Sugar Land Texas 77055
Investigational Site Number 840063 Kennewick Washington 99336
Investigational Site Number 840018 Tacoma Washington 98431

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 363 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00694382, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 22, 2013 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00694382 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →